Keyphrases
Profile Evaluation
100%
Moxifloxacin
100%
Pharmacokinetic Profile
100%
Legionella Pneumophila
80%
Haemophilus Influenzae
60%
Cmax
60%
Population Pharmacokinetic Model
40%
S. Pneumoniae
40%
Intravenous Administration
20%
Ultra-high Performance
20%
Concentration-time Curve
20%
Antimicrobial
20%
Therapeutic Outcome
20%
Pharmacokinetics
20%
Multidrug-resistant Pathogens
20%
Streptococcus Pneumoniae
20%
Drug Concentration
20%
Plasma Concentration
20%
Liquid Chromatography
20%
Resistance Emergence
20%
Therapy Initiation
20%
Pharmacokinetics-pharmacodynamics (PK-PD)
20%
Monotherapy
20%
Clinical Breakpoints
20%
Oral Administration
20%
MIC Values
20%
Target Attainment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Community Acquired Pneumonia
100%
Pharmacokinetic
100%
Moxifloxacin
100%
Infectious Agent
50%
Haemophilus influenzae
50%
Drug Concentration
33%
Streptococcus pneumonia
16%
Legionella pneumophila
16%
Monotherapy
16%
Pharmacodynamics
16%